Zhejiang Haichang Biotech Co., Ltd.
4 clinical trials · Sponsor
◉ Watch Zhejiang Haichang Biotech Co., Ltd.
| Record | Firm | Date |
|---|---|---|
| Phase 2 Study of WGI-0301 Plus Lenvatinib in Patients With Advanced HCC (NCT07540832) | Zhejiang Haichang Biotech Co., Ltd. | 2026-09-01 |
| Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC (NCT07494435) | Zhejiang Haichang Biotech Co., Ltd. | 2026-06-01 |
| Phase 2 Study of WGI-0301 for Advanced HCC (NCT06309485) | Zhejiang Haichang Biotech Co., Ltd. | 2024-07-31 |
| A Phase I First in Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of WGI-0301 in Patients With Advanced Solid Tumors (NCT05267899) | Zhejiang Haichang Biotech Co., Ltd. | 2022-08-01 |
Track Zhejiang Haichang Biotech Co., Ltd. automatically
Every clearance here is in the API, with alerts when new ones post.